Drug-Induced Bullous Disorders Clinical Presentation

Updated: Apr 30, 2018
  • Author: David F Butler, MD; Chief Editor: William D James, MD  more...
  • Print
Presentation

History

Symptomatology of cutaneous reactions varies depending upon type and extent of skin involvement.

Eczematous or spongiotic drug reactions may be the result of previous contact sensitization to the drug or may occur de novo. Incidence of contact eczematous reactions to topical medications may be as high as 12.1%. Systemic contact eczematous reactions, which result from systemic exposure (eg, oral, parenteral, rectal, intravenous, inhalation) to a previous contact sensitized drug, are less common. Eczematous drug reactions begin with diffuse pruritus but may also cause headache, malaise, fever, nausea, vomiting, and diarrhea.

Acute generalized exanthematous pustulosis (AGEP) (toxic pustuloderma) is a result of a systemic medication in 90% of cases. Onset is abrupt, usually 1-5 days after starting the medication. Patients report a diffuse pruritic or burning painful eruption associated with fever, malaise, and sometimes prostration. Seventeen percent of patients have a history of psoriasis.

Fixed drug eruptions (FDEs) are a common cause of all drug eruptions, and their frequency is second only to urticaria/angioedema. Careful patient assessment usually reveals that an FDE develops 6-48 hours after administration of the causative drug. Symptoms of pruritus and burning accompanied by fever are not uncommon. In those patients with multiple episodes of FDE, reports of increasing hyperpigmentation at the site of a previous lesion are common.

Nosology of EM is controversial and somewhat confusing. Historically, EM has been divided into 3 groups: EM minor, EM major or SJS, and TEN. Considerable overlap may exist between these 3 subgroups, and some authorities believe that TEN should be considered a distinct entity. An infectious agent, such as herpes simplex or mycoplasma, usually causes less extensive involvement of EM; drugs are implicated less often in EM minor. However, drugs cause most of the more severe and diffuse forms of EM. See the following:

  • EM minor may begin with prodromal symptoms suggestive of an upper respiratory infection (eg, coryza, cough, pharyngitis), but within 7-10 days skin lesions begin to develop acrally and symmetrically on the hands, feet, and distal extremities. EM minor may have involvement of the oral mucosa, but involvement of 2 or more mucosal surfaces usually indicates SJS or TEN.

  • EM major (SJS) affects young adult males more frequently. Prodromal symptoms of high fever, asthenia, muscular pains, diarrhea, vomiting, arthralgias, and pharyngitis precede mucosal involvement of 2 or more mucosal sites by several days. Skin involvement rapidly ensues. TEN has similar symptomatology but also demonstrates diffuse skin tenderness that resembles severe sunburn.

Drug-induced pemphigus can develop days, weeks, or months after taking the offending agent. Ruptured bullae leave painful erosions. Itching is not a common symptom. The oral mucosa is frequently involved; hoarseness, dysphagia, and unpleasant mouth odor follow. Drugs may serve as either a cause or a trigger for pemphigus. In those patients in whom drugs serve as a trigger, other autoimmune disorders such as lupus, bullous pemphigoid, and myasthenia gravis may already be present. Therefore, the development of drug-induced pemphigus seems to be determined in part by genetic predisposition.

Drug-induced pemphigoid may follow oral or topical administration of drugs. Itching is a common symptom. Involvement of the epiglottis may lead to acute airway obstruction. Patients with drug-induced pemphigoid are commonly younger than patients with idiopathic pemphigoid. Cicatricial pemphigoid is more common in patients of late middle age.

Drug-induced linear IgA dermatosis (LAD) comprises a small portion of all cases of LAD. The clinical presentation of drug-induced LAD is indiscernible from other causes of LAD, except that mucosal involvement may be less likely in drug-induced LAD. Drug-induced LAD usually develops 1-2 weeks after taking the offending agent, although reactions may develop much sooner. Patients who develop LAD usually are seriously ill. Symptoms of severe burning and pruritus are common.

Porphyria cutanea tarda (PCT) may be precipitated or exacerbated by estrogens, iron overload, environmental hepatotoxins, and several drugs, but patients who have drug-induced pseudoporphyria have no underlying abnormality of heme biosynthesis. The symptoms of photosensitivity, skin fragility, and blistering of the hands and forearms are the same in both conditions.

Blistering and increased skin fragility was noted on the hands, legs, and feet of a woman who was given the tyrosine kinase inhibitor, imatinib. The patient had loss of laminin and type IV collagen as a possible cause. [32]

Hemorrhagic blisters have been reported to be induced by low molecular weight heparin. [33]

Next:

Physical Examination

The physical findings of bullous drug eruptions vary greatly depending on the type of reaction.

On physical examination, the features of an eczematous drug eruption are similar to that of a diffuse contact dermatitis. These features include diffuse patches of erythema, microvesiculation, vesicles, crusts, and oozing. Other more specific features may include dyshidrotic hand dermatitis, EM-like lesions, purpura, urticarial lesions, and vasculitislike lesions. Recrudescence of a positive patch test reaction may occur after systemic exposure to the offending medication. A diffuse eczematous eruption may mimic severe atopic dermatitis.

Acute generalized exanthematous pustulosis (AGEP) manifests as a diffuse scarlatiniform rash that rapidly develops numerous (>100) small pustules. Pustules measure 1-5 mm (see the image below). Nikolsky sign may be positive. Some pustules may coalesce into bullae. Facial swelling, purpura, and targetoid lesions may occur. Oral mucosa may be involved in about 20% of cases. Once the offending drug is discontinued, the eruption rapidly dries up and desquamates within 2 weeks.

Small pustules on erythematous patch (acute genera Small pustules on erythematous patch (acute generalized exanthematous pustulosis).

Fixed drug eruptions (FDEs) start as a few sharply demarcated erythematous macules that rapidly become erythematous plaques occurring more commonly on the lips, genitalia, and trunk. Lesions heal with hyperpigmentation and occur in the same site with readministration of the responsible drug (see the image below). In 30% of cases, macules may become vesicles and bullae, which may lead to a more severe reaction known as generalized bullous FDE resembling SJS-TEN. In patients with generalized bullous FDE, physical examination reveals clearly demarcated erythematous and edematous patches surrounded by bullae that contain clear fluid.

Annular hyperpigmented patch (fixed drug eruption) Annular hyperpigmented patch (fixed drug eruption).

The characteristic physical finding of EM is the target or iris lesion. These lesions begin as sharply marginated erythematous annular macules or patches that become slightly raised (see the image below).

Target or iris lesions on palm (erythema multiform Target or iris lesions on palm (erythema multiforme).

A concentric color change takes place; the center of the lesion becomes darker, dusky, or more violaceous, and the periphery develops a ring of erythema. The classic iris lesion has 3 zones, a central dusky area with purpura and an edematous pale ring surrounded by an erythematous ring. The central dusky macule may actually form a tense vesicle or bulla. These typical iris or target lesions are more commonly observed in EM minor caused by infections and occur acrally and progress in a centripetal fashion. Larger, confluent, irregularly shaped, coalescing lesions with involvement of the trunk and 2 or more mucosal sites are common with SJS (see the image below). The mouth and lips are the most commonly affected mucosal site in SJS, but other sites such as the pharynx, larynx, esophagus, bronchi, and genital mucosa may be involved.

Coalescing eroded patches (Stevens-Johnson syndrom Coalescing eroded patches (Stevens-Johnson syndrome).

TEN demonstrates diffuse sunburnlike erythema that often begins on the face and spreads downward. The hairy scalp is spared. Maximal extension occurs within 2-3 days. A characteristic feature of TEN is the sheetlike separation of the epidermis in the involved areas. Flaccid bullae may form. Nikolsky sign is positive. Two or more mucosal sites are involved in 85-95% of patients with TEN.

Drug-induced pemphigus may be clinically indistinguishable from idiopathic pemphigus vulgaris or pemphigus foliaceus (see the image below). Lesions are superficial flaccid bullae ranging in size from 1-10 cm. They may initially occur in the mouth. Nikolsky sign is positive when pressure is applied lateral to the bulla. Lesions rupture easily, leaving denuded and weeping areas, which secondarily become crusted.

Crusted erosions on scalp (drug-induced pemphigus) Crusted erosions on scalp (drug-induced pemphigus).

Tense bullae on normal skin or on an erythematous base is the typical finding in drug-induced pemphigoid (see the image below). Denuded areas, which are left after bullae rupture, heal spontaneously. Erythematous patches, urticarial plaques, and targetoid lesions may also be observed. Lesions may be found on the face, trunk, limbs, palms, soles, and mucous membranes. Nikolsky sign may be positive, unlike in idiopathic pemphigoid. Cicatricial pemphigoid is distinguished from other forms of pemphigoid by the presence of scarring. Cicatricial pemphigoid occurs on the mucous membranes of the eyes, pharynx, genitalia, or anus. Adhesions, strictures, and the loss of function may result from the scarring process.

Small vesicle at edge of urticarial plaque (drug-i Small vesicle at edge of urticarial plaque (drug-induced pemphigoid).

Physical examination of a drug-induced LAD lesion may reveal one of several pictures. The most common presentations include urticated plaques, papulovesicles resembling dermatitis herpetiformis, targetoid lesions as in EM, and bullae resembling those found in bullous pemphigoid (see the image below). Bullous eruptions can become hemorrhagic. Lesions are most commonly located on the trunk and limbs. Cases of palmar lesions, although uncommon, have been reported.

Tense vesicles in annular array (linear immunoglob Tense vesicles in annular array (linear immunoglobulin A dermatosis).

Pseudoporphyria demonstrates tense blisters, erosions, and milia especially on the dorsum of the hands and forearms (see the image below). Features of hypertrichosis, dyspigmentation, and skin sclerosis are not observed in pseudoporphyria as they are in true porphyria.

Erosions, scars, milia, and vesicle (pseudoporphyr Erosions, scars, milia, and vesicle (pseudoporphyria).
Previous